Efficacy of Vagus Nerve Stimulation in Patients with Drug Resistant Epilepsy

Objectives: Vagal nerve stimulation (VNS), is an adjunctive therapy approved for use in patients with refractory epilepsy, based on stimulation of the exctracranial part of the vagus nerve. In this study, we provide an analysis of seizure outcomes after VNS implantation for pharmacologically resistant epilepsy patients. Methods: We reviewed all patients who had VNS implantation in our center from 2005 to June 2013. Patient outcomes were evaluated using the VNS-specific outcome scale. Results: This study consisted of 35 patients (24 males, 11 females; mean age 13.7 +/- 8.2 years, range 7 to 40 years). The mean age at VNS implantation was 17.17 +/- 8.4 years (range 4 to 35 years). The mean duration of VNS therapy was 26 +/- 19.2 months (range 3 to 84 months). The 80% of our patients were in the responders, 20% of them were in the nonresponders group. Conclusion: Vagal nerve stimulation, is an alternative treatment approach. Given the potential for cognitive, behavioural improvement with or without improved seizure control, VNS may be considered in the course of treatment of refractory epilepsy.